Womer K L, Guerra G, Dibadj K, Huang Y, Kazory A, Kaplan B, Srinivas T R
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Transpl Infect Dis. 2007 Sep;9(3):244-8. doi: 10.1111/j.1399-3062.2007.00204.x. Epub 2007 Jul 1.
BK virus nephropathy (BKVN) is increasingly recognized as a major cause of renal allograft failure. Recent reports demonstrate that prompt reduction of immunosuppression upon detection of persistent viremia can be associated with resolution of viremia, with minimal risk of acute rejection (AR). However, these experiences in general have occurred in centers with low baseline risks of AR. It is possible that a finer balance between overimmunosuppression and the risk of AR may exist in centers that routinely transplant patients with higher risk of AR. Thus the risk/benefit of this strategy may be altered in these centers. We report a case of antibody-mediated rejection that followed reduction of immunosuppression for BKVN diagnosed more than 3 months after the onset of viremia. This rejection episode resulted in a greater decrease in graft function than the initial BKVN episode. Issues relevant to the management of these patients are discussed, including the need for improved immune monitoring assays to determine more accurately the balance between infection and rejection.
BK病毒肾病(BKVN)日益被认为是肾移植失败的主要原因。最近的报告表明,在检测到持续性病毒血症后迅速降低免疫抑制可能与病毒血症的消退相关,急性排斥反应(AR)的风险最小。然而,这些经验总体上发生在AR基线风险较低的中心。在常规移植AR风险较高患者的中心,可能在免疫抑制过度与AR风险之间存在更精细的平衡。因此,在这些中心,该策略的风险/收益可能会改变。我们报告了1例抗体介导的排斥反应病例,该病例发生在病毒血症发作3个多月后诊断为BKVN而降低免疫抑制之后。这次排斥反应导致移植肾功能下降的幅度比最初的BKVN发作更大。讨论了与这些患者管理相关的问题,包括需要改进免疫监测检测方法,以更准确地确定感染与排斥之间的平衡。